180 Life Sciences (NASDAQ:ATNF) Given “Sell (E+)” Rating at Weiss Ratings

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating reiterated by equities research analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

180 Life Sciences Stock Down 4.3%

NASDAQ:ATNF opened at $0.83 on Friday. The business’s 50 day moving average is $1.01 and its two-hundred day moving average is $1.25. 180 Life Sciences has a 52 week low of $0.66 and a 52 week high of $17.75.

180 Life Sciences (NASDAQ:ATNF) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.67) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Anson Funds Management LP bought a new position in 180 Life Sciences Corp. (NASDAQ:ATNF) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned 7.08% of 180 Life Sciences as of its most recent SEC filing. 4.07% of the stock is currently owned by institutional investors and hedge funds.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.